Market Analysis and Insights: Global Pancreatic Amylase Reagent Kits Market
Due to the COVID-19 pandemic, the global Pancreatic Amylase Reagent Kits market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, R1: 5x20ml, R2: 1x25ml accounting for % of the Pancreatic Amylase Reagent Kits global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Pancreatic Disorders segment is altered to an % CAGR throughout this forecast period.
China Pancreatic Amylase Reagent Kits market size is valued at US$ million in 2021, while the US and Europe Pancreatic Amylase Reagent Kits are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Pancreatic Amylase Reagent Kits landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Pancreatic Amylase Reagent Kits include DIALAB GmbH, DiaSys Diagnostic Systems GmbH, Randox Laboratories Ltd., Abbott, Danaher, Biocompare, Vitro Scient, Merck and Biosystems S.A.. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Pancreatic Amylase Reagent Kits Scope and Segment
Pancreatic Amylase Reagent Kits market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Pancreatic Amylase Reagent Kits market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
R1: 5x20ml, R2: 1x25ml
R1: 5x80ml, R2: 1x100ml
R1: 1x800ml, R2: 1x200ml
R1: 1x1000ml, R2: 1x250ml
Segment by Application
Pancreatic Disorders
Cancer
Cystic Fibrosis
By Company
DIALAB GmbH
DiaSys Diagnostic Systems GmbH
Randox Laboratories Ltd.
Abbott
Danaher
Biocompare
Vitro Scient
Merck
Biosystems S.A.
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE